Last reviewed · How we verify
Mavik
At a glance
| Generic name | Mavik |
|---|---|
| Sponsor | Dr. Reddy's Laboratories Limited |
| Target | Angiotensin-converting enzyme |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Chronic heart failure
- Hypertensive disorder
- Left ventricular cardiac dysfunction
Common side effects
- Cough
- Dizziness
- Diarrhea
Serious adverse events
- Myocardial infarction
- Cardiac failure
- Cerebral hemorrhage
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Agranulocytosis
- Pancytopenia
- Renal failure
- Eosinophilic pneumonitis
- Hepatitis
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Trandolapril 4 mg Tablet Under Non-Fasting Conditions (PHASE1)
- Trandolapril 4 mg Tablet Under Fasting Conditions (PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (PHASE4)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mavik CI brief — competitive landscape report
- Mavik updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI